Paul Gillard | MSS, Med Science and Strategy
PPD, part of Thermo Fisher Scientific

Paul Gillard, MSS, Med Science and Strategy, PPD, part of Thermo Fisher Scientific

Dr. Paul Gillard is a seasoned professional in the field of vaccine development. An alumnus of the University of Brussels where he acquired his medical in ‘93 and internal medicine in ‘98 degrees, Dr. Gillard has dedicated over 18 years to the clinical development of prophylactic vaccines, including vaccines against human rotavirus, pandemic influenza, and tuberculosis.

Dr. Gillard's experience extends to leading vaccine development projects from Phase I through to Phase IV, dealing with a broad range of vaccine technologies, indications, and target populations. His professional journey includes significant experience in liaising with regulatory agencies such as the US FDA and EMA, including the submission of regulatory filings for licensure. 

Appearances:



Day 2 - Wednesday 30th October @ 14:00

Pragmatic & Emerging Strategies to Drive Efficiency in Large Phase III Vaccine Trials

last published: 10/Jul/24 14:15 GMT

back to speakers